LAIR1

Across TCGA pan-cancer cohorts, LAIR1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LAIR1 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LAIR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LAIR1 expression acts as an unfavorable survival marker.

PDAC, LUAD, and UCEC are the cancer types where LAIR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.303	0.490	.001	35	view →
LUAD	OS	Median	III,IV	0.298	0.808	.013	13	view →
UCEC	DFS	Quartile	All	0.828	1.000	.019	10	view →
CCRCC	DFS	Median	All	0.687	1.000	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LAIR1–PDAC (DFS)

Open the PDAC breakdown →